Atherosclerosis is the most common form of vascular disease and constitutes the major cause of death, with 17.5 million related deaths annually (31% of global mortality). Atherosclerotic plaque represents the hallmark lesion of atherosclerosis. Most, but not all, acute cardiac events occur in the context of plaque-related thrombus formation, with the remainder associated with primary cardiomyopathy or arrhythmogenesis (primary myocardial electrical instability or ischemia related). Given that advances in technology allow for imaging, access, and localized treatment of atherosclerotic plaques, enormous efforts have been devoted to recognizing "vulnerable plaques," defined as rupture-prone (or, more teleologically relevant, event-prone) plaques and, subsequently, treating them.

Despite the above, results of vulnerable plaque-oriented approaches, in terms of both personalized risk assessment and guided treatment effects, have generally been poor, thus raising doubts regarding the validity and usefulness of the vulnerable plaque concept. In the present review, processes associated with decreased stability and related to the vulnerable plaque hypothesis, along with current and experimental methods for detecting vulnerable plaques, are discussed. Finally, potential alternative strategies, representing an amalgamation of differing views of atherosclerosis, will be explored.

On the Genesis of Atherosclerotic Plaque

Disruption of the endothelial cell-mediated vessel lumen-wall barrier is considered the earliest prodrome lesion of atherosclerosis. The molecular basis of the barrier lies in intercellular (tight and adherens junctions) and cell/extracellular matrix (ECM) adhesion, both being necessary for its integrity. Both structures are linked to the cytoskeleton, thus allowing for cellular adaptation to applied stresses. In fact, these stresses and consequent induced strains (deformations) are sine qua non stimuli for barrier maintenance, acting through mechanosensor-mediated signal transduction pathways (involving actin and integrins). Furthermore, endothelial cells lose their polarized structure and assume a spindle-like conformation, expressing leukocyte adhesion molecules. Consequently, areas of the vasculature with inherently low transmural and shear stresses (cause) and strains (effect), such as bifurcation points and the inner wall of curved vessels (such as the right coronary artery), may begin developing barrier defects early in life.

Lipid-Driven Mechanisms

These breaches of vascular barrier integrity allow for lipoprotein infiltration and deposition in the intima. Uptake by both locally present and recruited macrophages attempts to prevent their accumulation by means of reverse cholesterol transport. However, cholesterol does have deleterious cellular effects, causing apoptosis, initiating inflammation and thus preventing its removal. Upon further material accumulation, an amorphous lipid core (hence the component “athero,” from the Greek αθήρα, meaning gruel) is formed—the infamous necrotic core. Lipid particles residing in the core undergo enzymatic modifications, becoming oxidized, and trigger the release of proinflammatory mediators. Additionally, oxidized low-density lipoprotein (LDL) has been found to trigger necroptosis, an alternate form of programmed cell death, originally a defensive infection mechanism, whereupon cells do not quietly implode, but rather release particles and messengers inducing proinflammatory activation of adjacent cells. Thus, lipid accumulation and modification strongly enhances both quantitative and qualitative plaque progression. Activated macrophages and apo-/necroptotic cells within the necrotic core produce tissue factor (factor III), a major component of 1 coagulation pathway, significantly enhancing its thrombogenicity.
Lipoprotein(a) (Lp(a)) is a specialized molecule thought to have arisen recently in evolutionary history, either in the context of infection control (given its ability to amass oxidized lipids and draw inflammatory cells to injured vessel walls—normally caused by infectious agents, not atherosclerosis) or as a surrogate for ascorbic acid in vascular wall repair. However, in the context of atherosclerosis, it assumes 4-fold deleterious/distabilizing effects by promoting thrombosis, inflammation, cholesterol delivery to atheromas, and smooth muscle cell (SMC) proliferation. Studies’ findings have, foreseeably, associated Lp(a) levels with vulnerable plaque phenotype.

**Inflammatory-Immune Mechanisms**

Inflammation is also a major event in atherosclerosis natural history and plaque progression, usually related to decreased structural stability. Both components of immunity, innate and adaptive, have been found to be activated in atherosclerosis-related inflammation. Postulated infectious mechanisms (*Chlamydia pneumoniae*) also act through this pathway, although the process soon becomes self-sustained regardless of pathogen presence. Increased local thermal activity has been considered a direct effect of inflammation, stemming from presence of metabolically highly active immune cells, energy production uncoupling attributed to ischemia, and exothermic chemical reactions (such as oxidation, H$_2$O$_2$ dissociation). Moreover, given results of theoretical calculations, blood-wall friction as well as turbulent flow at the maximal stenosis area also contribute to localized heating. Increased temperature is not only a potentially measurable result of atherosclerotic plaque presence, but has also been related to higher blood viscosity and red cell aggregation. Finally, neovascularization of advanced plaques might also play a role, on the premise of heating the metabolically more-inert abluminal area and core of the plaque, although a cooling effect of blood-flow-related convection should be considered.

**The Role of ECM**

A second dynamic equilibrium is established regarding ECM production and degradation, giving rise to vessel remodeling, that is, the response of the ever-changing plaque to alterations in mechanical factors. ECM, comprised of both cellular and acellular (usually in the form of proteoglycans) components constitutes the initial, theoretically temporary, container of the necrotic core, preventing its contact with the bloodstream. Furthermore, the mechanical strength of its luminal part (cap) determines plaque resistance to stress. SMCs and myofibroblasts are the main producers and maintainers of ECM, with inflammatory cells and necrotic core stimulating its degradation.

ECM degradation is not limited to the luminal side of the plaque; rather, abluminal layer involvement is evident, especially in plaques with larger necrotic cores (and, consequently, more macrophages and inflammation), providing a mechanistic link and interpretation of the well-known association between positive remodeling, plaque necrotic core size, and instability. Furthermore, direct deleterious effects of the necrotic core have been documented, in the form of cholesterol crystals that expand upon formation and with changes in temperature and pH, rupturing container (foam) cells and straining the plaque from within (not unlike ice), and pierce the fibrous cap, weakening it and providing a thrombogenic substrate to circulating coagulation components. In fact, the relationship between cap thinning and plaque propensity to rupture is not linear, given that significant increases in deformation and tensile stress, for the same load, are noted past a certain point (Young’s modulus reduction >60%).

**Neoangiogenesis**

Neoangiogenesis is a feature of advanced atherosclerosis, appearing late in the natural history of plaques. The main stimulus for neovessel formation comes in the form of hypoxia-inducible factors secreted by hypoxic macrophages deep in the lesion’s necrotic core and involves endothelial cells losing polarity and sprouting tube-like forms as precursors to fully fledged neovessels. In fact, the anoxemia theory of atherosclerosis postulates that it is the depletion of ATP in macrophages, attributed to the extremely high rates of energy taxing cholesterol uptake, which leads to apoptosis, formation of a necrotic core, and angiogenetic stimuli. The neovessel wall lacks proper structure, in terms of elastic laminae and smooth muscle cell support, and thus they are leaky, prone to rupture, and provide the plaque with elements crucial for its continued progression, in the form of cholesterol (both lipoprotein and red blood cell membrane derived), cytokines, and leukocytes, straight to the necrotic core, thus establishing a vicious positive feedback loop favoring destabilization and, ultimately, rupture. Plaque hemorrhage may thus underlie episodes of accelerated plaque growth.

**The Many Faces of Mineralization**

The final act in the course of atherosclerosis as a chronic unresolved inflammatory process lies in the permanent and secure encasement of its source area in a highly calcified structure (mineralization), replacing the temporary fibrotic “seal” produced by chemokine-attracted intima invading SMCs. The process of vascular mineralization is now considered active, highly regulated, and akin to bone formation. Notably, vascular calcification, as opposed to bone formation,
appears to be triggered, not inhibited by, inflammation. However, in a process reminiscent of myocardial wall rupture risk following infarction, initial phases of calcification with formation of calcified specs and nodules (microcalcification) will actually reduce plaque mechanical strength by introducing contact areas between materials (calcified nodules and fibrous cap components) with different elastic moduli, different behavior under stress, and thus prone to stress-induced debonding or caveolation. This effect is particularly prominent in cases of adjacent specs, interpreting central plaque rupture and high peak stresses in theoretically nonvulnerable (cap thickness >65 μm, or even >100 μm) plaques. The above could help explain the often contradictory findings regarding calcification effects on plaque stability, given that older imaging modalities could not reliably discern between spotty/nodular calcification and fused, reinforced calcified structures.

The Divergent Course of Erosion

Plaque erosion mechanisms underlie almost one quarter of all acute coronary syndrome (ACS) events, with rising prevalence, yet they remain largely unresolved. Eroded plaques tend to lack features associated with rupture prone structure, exhibiting thicker caps, large numbers of SMCs, and smaller necrotic cores, while being quiescent in terms of inflammation. However, significant divergence has been documented in terms of ECM properties. Both a shift toward collagen III (as opposed to collagen I usually dominating plaque ECM) and hyaluronan (a proteoglycan subtype) production has been found—in fact, hyaluronan is almost absent even at rupture sites. Given that collagen III has more-elastic properties, compared to its type I counterpart, and that endothelial cell adhesion to hyaluronan is reduced (especially in larger-vessel–derived endothelial cells), detachment of cells from their basal membrane becomes possible, even at lower stresses—or in cases of coronary spasm (increased membrane mobility and weaker attachment). Furthermore, not only is hyaluronan more susceptible to neutrophil-derived protease cleavage, but also increased numbers of neutrophils have been detected near erosion-prone plaques as well and have been shown to induce endothelial apoptosis. Finally, hyaluronan itself has been associated with reduced proliferation and survival of endothelial cells in cultures and possesses prothrombotic properties (increased platelet adhesion and accelerated fibrin polymerization). Given preponderance of women, smokers, diabetics, and the elderly among patients suffering plaque erosion, it could be inferred that certain idiosyncratic features or noxious (metabolic or exogenous) stimuli alter the usual course of events during atherosclerosis progression, leading to formation of a less-ruptured (increased elasticity?), yet more thrombosis-prone plaque. The lack of need for structural support with exogenous scaffolding and increased thrombogenicity may interpret the findings of the recent Effective Antithrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion (EROSION) study, where antithrombotic therapy was a viable option, compared to stenting, in nonocclusive stenoses causing erosion-related acute events. The enhanced role of neutrophils in plaque erosion—allogens to that of macrophages in rupture—is thought to be mediated by released strands of DNA, called neutrophil extracellular traps (NETs), originally sequestering pathogens and disarming them by means of DNA-drawn enzymes. However, in the framework of plaque erosion, the process, aptly termed NETosis, leads to a prothrombotic state, by enhancing platelet aggregation and coagulation and inhibiting fibrinolysis (fibrin mesh constituting another putative pathogen trap). Indeed, myeloperoxidase-positive cells have been found in larger quantities in the blood of patients with eroded plaques and in the overlying thrombi.

Effects of Plaque Environment—External Stresses

Effects of abnormal exogenous stresses continue in late stages of atherosclerosis. Normal laminar flow causes relatively stable transverse and shear stresses, with limited oscillatory variations. Moreover, in addition to cell reorientation, exogenous stress leads to collagen laminae reorientation, introducing anisotropy of the fibrous cap and rendering it more prone to rupture. Mechanical factors may also, through mechanoreceptors, lead to a multitude of effects on other cellular processes, such as increased reactive oxygen species (ROS) production and inflammation. In fact, plaque tendency to rupture at the shoulders, as well as cases of fissuring in other areas of the fibrous cap, may be interpreted by integrating mechanical factors’ effects on biology. As blood flow is diverged toward the remaining lumen by the upstream plaque edge, a low-stress area occurs, prone to loss of cellular architecture and increased lipoprotein and leukocyte permeability, thus continuously providing fuel for plaque growth and inflammation. At the shoulder area, however, stresses increase considerably attributed to blood incompressibility. Thus, not only are ROS production and inflammation stimulated in the underlying tissue (as a result of high, rather than low, stresses in this area), but an abrupt transition between mildly and highly stressed areas occurs, favoring plaque rupture and neovessel formation and rupture. Similarly, at the downstream shoulder, flow turbulence leads to decrease of transmural pressure attributed to vortex-formation–related energy dissipation, mirroring the events of the upstream region. Presence of a large necrotic core exaggerates this unfavorable altering of stress distribution, further straining the
shoulder area. At intermediate plaque areas, between shoulders, highly oscillatory stresses may occur attributed to the Bernoulli effect. Similarly, this mechanism of blood acceleration through the stenotic lumen and reduction of transmural pressure exerts detrimental effects on the vasa vasorum with blood content oscillations, causing plaque expansion and dilation at every cardiac cycle, stressing and building up fatigue in the fibrous scaffold of the plaque, and potentially causing the structurally defective vasa vasorum to rupture. High shear stresses could conceivably play an analogous role in enhancing endothelial cell denudation in plaque erosion. Based on the above, it is evident that all types of abnormal stress patterns, if sustained, have discrete adverse effects on atherosclerotic lesions: Low stresses are involved in initial stages, whereas high and oscillatory stresses come into play later on in disease progression.

**Vulnerable Plaque Hypothesis**

Ultimately, plaque destabilization (a general term for complication related changes) is a biomechanical phenomenon that can be thought of as depending on a complex interplay between applied stresses, structural features, and biological processes that determine mechanical strength. This approach, although not conclusive, is useful as a framework for pursuing ways to prevent, predict, and avert rupture/erosion. Obviously, focusing solely on plaque characteristics will ignore the effects that exogenous forces exert on stability. On the other hand, focusing on luminal stenosis will only assess the applied forces and disregard plaque contribution, explaining the oft-cited finding of far greater prevalence of nonstenotic lesions in cases of destabilized (ruptured) plaques.

Furthermore, not all cases of destabilization will lead to clinical events, given that vessel occlusion, leading to peripheral necrosis with mechanical or electrical instability, is associated with blood thrombogenicity and the ability of counter-regulatory mechanisms to contain its sequelae—prevalence of silent ruptures in stable coronary artery disease patients has been reported to reach 58%. Plaque rupture is the most common form of plaque destabilization, accounting for two thirds of fatal myocardial infarctions (MIs) and sudden cardiac deaths and refers to transmural fissuring of the fibrous cap, leading to exposure of the thrombogenic and proinflammatory underlying necrotic core to circulating blood. The affected plaque usually has the features of a thin cap fibroatheroma, as described previously (Table 1). On the other hand, plaque erosion denotes a histologically seen thrombus superimposed on a cell-denuded endothelial layer of a nonruptured plaque with different structural features, as observed in the alternative course of plaque progression. Finally, calcified nodules have been found in cases of culprit lesions, as expected by their inherent disruptive effects on plaque integrity, constituting another rupture-prone structure, alternative to thin cap fibroatheroma.

The vulnerable plaque hypothesis was developed in an effort to better describe the unpredictability of the clinical course of atherosclerosis. Vulnerable plaques have insightfully been defined as those plaques prone to becoming culprit plaques (Table 2), causing acute vascular events or death, regardless of form, shape, stenosis, or destabilization. Consequently, all forms of rupture-prone, erosion-prone, hemorrhaging, or containing calcified nodules plaques (mainly expressing the intrinsic constituent of culpability potential), as well as significantly stenotic plaques (mainly expressing the extrinsic constituent in the form of applied stresses), can be considered vulnerable plaques as long as they have led to

### Table 1. Thin Cap Fibroatheroma Features

<table>
<thead>
<tr>
<th>Feature</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap thickness</td>
<td>≤65 μm (based on results by Burke et al)</td>
</tr>
<tr>
<td>Large necrotic core</td>
<td></td>
</tr>
<tr>
<td>Increased macrophage infiltration</td>
<td></td>
</tr>
<tr>
<td>Focal lesion, containing necrotic core (≥10% of total plaque area) in direct contact with the lumen (cap cannot be visualized)</td>
<td></td>
</tr>
<tr>
<td>Percent atheroma volume</td>
<td>≥40%</td>
</tr>
<tr>
<td>Optical coherence tomography</td>
<td>3-D, 4-D, 5-D, 6-D</td>
</tr>
<tr>
<td>Wide lipid arc (&gt;90 degrees), suggesting increased lipid content. Lipid arc is defined the widest arc demarcating a signal poor region with diffuse borders</td>
<td></td>
</tr>
<tr>
<td>Necrotic lipid pools presence (signal-poor regions poorly delineated, underlying a signal rich cap), quantified based on number of quadrants occupied</td>
<td></td>
</tr>
<tr>
<td>Superficial microcalcifications (subtending a &lt;90-degree arc and with a border with lumen &lt;100 μm thick)</td>
<td></td>
</tr>
<tr>
<td>Cap thickness</td>
<td>≤65 μm—although different limits have been proposed, with studies suggesting that OCT-derived in vivo thin cap limit should be increased (postmortem/histological preparation—related alterations in previous studies)</td>
</tr>
<tr>
<td>When virtual histology IVUS is used concomitantly to assess deeper plaque layers, OCT fibroatheromas are confirmed to have a high lipid content and low levels of fibrosis and exhibit more-expansive remodeling</td>
<td></td>
</tr>
</tbody>
</table>

Modality-specific definitions are necessary, given that no single approach can accurately visualize all aspects of histology, attributed to poor resolution for IVUS and poor penetration for OCT. Given complimentary features of all methods, the best possible assessment of intrinsic instability (see Figure 1) would currently entail application of multiple modalities on a single plaque or, alternatively, combination of modalities into multifunctional systems. IVUS indicates intravascular ultrasound; OCT, optical coherence tomography.
Detecting the Vulnerable Plaque

Although the ability of imaging modalities to visualize atherosclerotic plaques has improved considerably during the past few years, they primarily focus, with few exceptions, on accurately depicting a still frame of the plaque structure, not the continuous and variable interaction with its surroundings (plaque-centered approach). Thus, none of them has, beyond the context of proof-of-concept studies, established criteria for assessing plaque vulnerability in the broader sense, as discussed previously.

Intravascular ultrasound (IVUS) is 1 of the 2 most widely used invasive coronary atherosclerotic plaque imaging modalities, the other being optical coherence tomography. Essentially a catheter-mounted ultrasound transducer, it follows the same principles regarding ultrasound generation, signal reception, data processing, and image presentation.63 A grayscale image is generated based on which plaques can be broadly classified as (their echogenicity compared to that of the fibrous adventitia) soft, intermediate, calcified, and mixed. Moreover, added modules can enhance tissue characterization abilities of IVUS, allowing for detection and quantification of different plaque structures—this is achieved, in broad, by analyzing, in addition to reflected signal amplitude, its frequency and power. Virtual histology IVUS, iMAP IVUS, and integrated backscatter IVUS are examples of this, with high reproducibility although they remain proprietary and use different color-coding for the same structures.73–75

Regarding vulnerable plaques, IVUS, and its modular expansions, can reliably assess plaque burden, expansive remodeling, as well as presence and relative proportion of necrotic core, calcifications, and neoangiogenesis (contrast enhanced; penetration depth, 5 mm). Confirmation of greater strains in fibroatheromatous, as compared to fibrous plaques, has also been provided by compound ultrasound strain imaging (alternatively known as palpography/elastography).76 However, at its current form (20/40 MHz transducers), it cannot visualize plaque caps, especially thinner ones (resolution, >100 μm).63 Most prospective studies regarding ability of vulnerable plaques to predict events used IVUS-based approaches in their definition of vulnerability.77–80

Optical coherence tomography (OCT) is the second major coronary plaque invasive imaging modality that uses near-infrared light (1.3 μm in wavelength) in a manner analogous to sonography. Light reflected form plaque structures provides image data whereas the background effect of scattered light is negated through use of interferometric techniques. Bright or dark areas occur as a result of constructive or destructive interference between reflected and reference beams. Given the much smaller wavelength of light in comparison to ultrasound, OCT resolution is 1 order of
magnitude higher (≈10 μm), allowing for proper visualization of fibrous caps, collagen content (polarization-sensitive OCT), macrophages (related to inflammation),81 neovessels (appearing as microchannels), ruptures, and thrombi. OCT performance, with regard to microcalcifications at the lower end of the spectrum (<5 μm in diameter), remains uncertain. Consequently, several, but not all, aspects of vulnerability are visualized. However, this comes at a price, considering that high scattering of light prevents imaging of plaque structures at deeper layers (penetration depth, 1.5 mm) and thus proper recognition and estimation of remodeling and necrotic core size (hence the “lipid arc” concept; Table 1).

OCT has displayed high agreement with histopathology regarding both plaque characterization and cap thickness.67 OCT limitations include the need for blood displacement, attributed to the high scattering effect of its components, longer image acquisition times (although newer, frequency domain analysis-based processing methods), frequent artifacts, inability to assess deeper plaque structures, as well as relatively poor discrimination between calcified areas and lipid core, given that both appear as signal poor areas (with clear and diffuse borders, respectively).58

A newer form of OCT, micro OCT (µOCT), is currently able to offer axial and lateral resolution in the order of 1 to 2 μm,
by means of advanced frequency domain analysis and use of broad bandwidth light, approaching histology levels. Thus, events in the cellular and molecular level, crucial to atherosclerosis development and progression, are visualized, including leukocyte diapedesis, fibrin strand formation, ECM production, endothelial denudation, microcalcifications and cholesterol crystal formation, and penetration of the fibrous cap. Given that this method may, in the future, offer real-time in vivo images (as well as 3-dimensional reconstruction) of the vessel wall at subcellular resolution, it may prove extremely useful for the classification of atherosclerotic plaques and identification of the vulnerable ones, replacing classical histology and scanning electron microscopy, notwithstanding all inherent classical OCT limitations.

Invasive coronary thermography is an approach aiming to detect subtle temperature increases of the vessel wall in areas of heat production, usually accompanying inflamed and/or ruptured atherosclerotic plaques.82 Purpose-built catheters include hydrofoil and balloon-based designs, ensuring adequate apposition of the thermistor module on the vessel wall.83,84 The latter is furthermore able to ensure temporary lumen occlusion, thus negating any cooling, convection-based effects of blood flow, and accentuating underlying gradients.84 Indeed, studies have shown both an increase in temperature correlating with presenting disease severity (stable angina<unstable angina<acute MI), and a correlation with systemic levels of inflammatory mediators, such as C-reactive protein.83 In addition, prognostic value of postangioplasty measured plaque temperature has been demonstrated, given that a difference of ≥0.5°C between plaque and healthy vessel wall was associated with 41% probability of adverse events (repeat infarction, recurrent angina, and death) during a follow-up period of just 18 months.85 Good correlation with IVUS-derived indices of vulnerability (positive remodeling) has been reported.82 Despite a sound pathophysiological basis, technical issues have, so far, precluded the use of thermography for plaque vulnerability assessment.

Near-infrared spectroscopy (NIRS) utilizes characteristic emission spectra produced by plaque contents following interaction with photons (wavelength area, 700–2500 nm). Low sensitivity, in terms of induced response, and high penetration, as compared with visible light spectroscopy, render this method appropriate for assessing the lipid content of plaques, especially in cases of positive remodeling, with large, deep-seated, lipid-laden necrotic cores.86 Studies using NIRS have shown that large lipid content, rather than plaque burden, is associated with thin cap fibroatheroma features.25,87 Larger lipid core burden has been shown to accurately differentiate between culprit and nonculprit lesion in ST-elevation MI patients88 and has been associated with higher risk for periprocedural myocardial infarction.89 Interestingly, combination with IVUS may allow for concomitant appreciation of both plaque structure and composition,90 comparing favorably with OCT.87 Despite recent studies linking lipid-rich, NIRS-defined nonculprit plaque presence with a 4-fold risk for adverse events (all-cause mortality, nonfatal ACS, stroke, and unplanned revascularization—excluding those definitely related to the initial culprit lesion)91 within the first year of follow-up, it cannot be inferred whether these were actually triggered by the detected vulnerable plaque (thus being amenable to preventive stenting) or by other, not assessed lesions (NIRS was only performed over a vessel segment). The latter could have very well been nonvulnerable lesions at the examination time, and their progression would reflect the need to reduce the atherosclerotic burden as a whole, rather than perform localized treatment. Results from the COLOR and LRP (Lipid Rich Plaque) studies are expected to shed light on the role of NIRS in guiding nonculprit vulnerable plaque stenting.92,93

A modified form of NIRS, near-infrared autofluorescence, involves active stimulation of lipid components to emit detectable infrared light.94 Combination with OCT has allowed for better visualization of lipid-laden necrotic cores and, moreover, accurate localization of the area within it with the densest macrophage concentration.95

Computed tomography coronary angiography (CTCA) utilizes a computed tomography (CT) scanner in combination with iodine intravenous dye to visualize the coronary arteries. Significant advantages stem from its very nature: noninvasiveness, ability for imaging the whole coronary vasculature, and potential for assessing both vessel wall in addition to the lumen.96 Advances in technology have allowed for improved image quality with reduced scan times and radiation exposure. More specifically, multislice (or multidetector) scanners possess a 2-dimensional detector array allowing for simultaneous acquisition of multiple planar images (slices), reducing examination time and possibility for motion artifacts—those with an array breadth of 160 mm allow for imaging of the heart in a single beat. Use of softer reconstruction kernels leads to improved soft-tissue visualization, however at the expense of spatial resolution.97 Prospective gating can thus be used in order to synchronize image acquisition with diastole (increased coronary blood flow). Moreover, advent of dual-energy monochromatic scanners may overcome limitations in tissue assessment caused by adjacent intense calcification, by negating the beam-hardening effect.98 Finally, dual-source scanners may complete the examination in only half a rotation. The related, albeit simpler, technique of calcium scoring does not use an intravenous dye and focuses primarily on coronary calcium quantification to predict the risk for subsequent events.

From a clinical standpoint, CTCA has emerged as the best noninvasive imaging modality in terms of assessing both
lumen area and plaque composition, throughout most of the coronary vasculature (vessels >1.5 mm in diameter, where the majority of plaques are located). Its accuracy in detecting lesion presence is noninferior to IVUS, and, consequently, it exhibits an excellent rule-out ability with a negative prognostic value approaching 100%, even in prolonged follow-up. Furthermore, although unable to quantify cap thickness, it is nevertheless able to detect presence of thin cap fibroatheromas, comparing favorably with OCT.

Regarding vulnerable plaques, CTCA can reliably assess the presence, size, and thickness of the necrotic core, by grading tissue in Hounsfield units (HU); plaques with large cores will cause less attenuation and thus have lower unit values. Specific high-risk plaque criteria have been developed, such as positive remodeling (remodeling index [RI] ≥1.1, also a surrogate for plaque composition), (very) low (given that the threshold for a ≥10% necrotic core is 41 HU) attenuation plaque (LAP; <30 HU), napkin-ring sign (a low attenuation core surrounded by a rim of relatively high attenuation—pathogenesis is still debatable), and presence of spotty calcifications (<3 mm—in accord with the role of calcium species in destabilizing plaques; see “The Many Faces of Mineralization” subsection).

It is noteworthy that all of its derived parameters regarding plaque characterization have emerged as significant and independent predictors of events in multiple studies. For example, a recent coronary CT study, with a follow-up of almost 100 months, confirmed that, in nonobstructive disease, positive remodeling, increased plaque burden, low attenuation, and napkin-ring sign presence are all associated with cardiac events. In addition, a plaque volume of 3 mm³/mm of vessel wall has been identified as an appropriate cutoff for prediction of adverse events. Presence of multiple high-risk features has been found to confer a more-than-additive risk, as reported in large studies. More specifically, presence of both positive RI and LAP yielded a more than 22% probability of ACS over an average follow-up of 27 months, as compared to <0.5% probability, should both features be absent. Presence of 3 high-risk features (LAP, RI, and napkin-ring sign) leads to a 60% survival free from ACS in the first year. In the latter study, the napkin-ring sign had the highest hazard ratio (HR) for occurrence of events (HR, 5.6).

Coronary artery calcium score (CACS) is an alternative parameter measured by means of cardiac CT without the need for intravenous dye. Despite the fact that it only assesses 1 aspect of atherosclerosis, as opposed to CTCA, it has been proposed that the latter offers additional prognostic information only in patients with intermediate to high CACS. In another study, a combination of traditional risk factors, CACS, and CTCA yielded an area under the curve of 0.93 for the prediction of major adverse cardiovascular events (cardiac death, nonfatal infarction, and revascularization) over a follow-up of ≈1000 days, significantly higher than that of the CACS—risk factors combination (0.82; P<0.001). The noninvasive nature of CTCA renders it an attractive option for population screening (primary prevention), and the ability to assess and monitor plaque burden essentially in the totality of the coronary arterial bed, with incremental improvement over conventional stratification, allows for the pursuit of risk-factor–reducing strategies as an alternative to pre-emptive stenting of high-risk asymptomatic lesions. CTCA-based 3-dimensional reconstruction of vessel anatomy and geometry has also been used for the noninvasive assessment of fractional flow reserve in order to determine hemodynamic significance of lesions; however a potentially more-fruitful approach could be its integration into fully fledged computational models for the assessment of plaque stability (see below).

As pointed out in the NIRS section, although these results encourage the use of CTCA as a means to assess probability for future events, they cannot constitute, in any way, a proof for the validity of stenting nonculprit vulnerable plaques, given that they do not prove that they underlay these events.

Magnetic resonance imaging (MRI) has the best ability to visualize the soft-tissue component of atherosclerotic plaques, as well as neovessel formation and diffusion properties (wall permeability). Major limitations include motion artifacts and use in cases of cardiac implants or devices. Importantly, MRI has been used in animal studies attempting to prospectively determine vulnerable plaque features specifically related with (pharmacologically induced) disruption. These were related to plaque remodeling (with positive remodeling and grater plaque area associated with future rupture) and inflammation indices (markedly increased gadolinium enhancement—denoting increased neovessel permeability and extracellular space expansion—as in intense apoptosis/necrosis). Even so, applicability to humans, the time frame between feature presence and (nontriggered) rupture and relation with clinical events remains unknown.

Molecular imaging involving targeting and visualizing specific components of biological processes, has been extensively used in attempts to visualize the vulnerable plaque. Theoretically, any modality may be used for molecular imaging as long as a proper tracer can be developed, for example, photon-emitting or possessing paramagnetic properties. Any substance of interest may act as a target provided that it can be either attached to or modified as a tracer. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are the 2 modalities mostly associated with molecular imaging, often in conjunction with CT/MRI imaging, to provide anatomic background.
and resolution on top of the mainly functional results of molecular imaging.

Virtually every atherosclerosis-related process has been studied by means of molecular imaging. More important, vulnerability-related processes have proven amenable to imaging, including leukocyte adhesion (through involved proteins, such as selectins and vascular cellular adhesion molecule 1), macrophage content (osteopontin), and collagen degradation (labeled matrix metalloproteinase [MMP] inhibitors), cell apoptosis (use of annexin that binds to lipids exclusively present in the outer layer of apoptotic cell membrane) or necroptosis (radiolabeled necrostatin, a preferential inhibitor of necroptosis), and neoangiogenesis (use of labeled anti−vascular endothelial growth factor antibodies as tracers). PET has also been experimentally evaluated for the study of intraplaque hypoxia and assessment of macrophage content. Significance of tracer choice can be perceived in the case of plaque calcification, where PET-CT use of radioactive sodium fluoride as a tracer may reveal sites of active calcification, thus differentiating between stabilizing (encasing) and destabilizing (ongoing) calcification (see above). This is achieved because of preferential binding of the tracer on hydroxyapatite crystals, whose exposed surface is much larger in areas of ongoing crystal formation.

PET is generally favored over SPECT because of lower artifact rates and improved spatial resolution as a result of detection of 2, as opposed to a single, oppositely moving photons.

The advent of nanotechnology has further widened the repertoire of imaging probes, allowing the construction of complex nanostructures (nanoparticles and magnetic nanoparticles), engineered according to the desired targets. For instance, nanoparticles composed of cross-linked iron oxide molecules and 19F perfluorocarbon are used to detect macrophages and in MRI spectroscopy, respectively (the latter attributed to excellent background noise suppression—no fluoride isotopes exist in tissues). Many of these probes may double as treatment vectors (theranostics), inasmuch as under the influence of infrared lasers from a catheter they overheat and release energy to the surrounding tissue, leading to (localized and targeted) irreparable damage (nanobombs).

Interestingly, different approaches to optical microscopy (Brillouin microscopy) could allow for direct estimation of plaque stiffness without need for computational models (see below). More specifically, they exploit differential energy shift of emitted photons following interaction with different areas of an anisotropically deformed (strained) structure (such as a plaque cap). Proof-of-applicability studies have been undertaken in an ex vivo setting, providing encouraging results regarding potential mounting of Brillouin scattering systems on coronary catheters.

Computational models will allow for simulation of plaque behavior under (patho)physiological conditions. These include finite element analysis models, assessing forces applied on a surface though numerical approximation of the solution by dividing the surface into multiple (>10 000) elementary components with homogeneous properties, and fluid−structure interaction simulations, also integrating rheological effects on plaque structural stress. They are the only means able to actually assess true vulnerability by integrating the plaque structure with its surroundings; however, all of them are critically dependent on an accurate imaging technique to provide vessel geometry and plaque structural data as input. Intrinsic parameters classically associated with vulnerability (cap thickness, necrotic core size, vessel anisotropy, and all forms of calcification) are combined with the anticipated effects of applied stresses, fatigue attributed to vessel motion during the cardiac cycle, and blood pressure/flow effects to yield meaningful results regarding conditions leading to rupture/erosion. Should more parameters be available as inputs and not need to be inferred (such as stain by use of Brillouin microscopy), results will accordingly be more precise. A major limitation of current computational models lies in the perceived difference of structural properties between plaque components in vivo and purified materials used to determine inserted parameters. Despite the above, advances in algorithms have led to reduction of necessary time to construct the model and obtain convergent solutions (ie, functions describing plaque behavior) from weeks (!) to less than 2 hours. The latter is comparable to offline time needed for 3-dimensional reconstruction of IVUS and OCT data; thus, it may herald active application of models to clinical practice in the near future so as to evaluate the atherosclerotic plaque not as an isolated structure, but as part of a living vessel.

Although relatively scarce, some clinical data exist advocating the added prognostic value of integrating computational models in clinical practice. More specifically, even in the negative Prediction of Progression of Coronary Artery Disease and Clinical Outcome Using Vascular Profiling of Shear Stress and Wall Morphology (PREDICTION) study, wall shear stress was found predictive of a future decrease in luminal area and clinically significant obstruction, whereas balloon-induced rupture was noted to occur at the site of the maximal structural stress in a 2001 study using IVUS to generate a finite-element model. More important, in patients presenting with ACSs, increased stress values were noted in high-risk areas, suggesting a potential cause-and-effect relation. Obviously, large, well-designed prospective studies and, subsequently, randomized, clinical trials are currently lacking and sorely needed to verify or refute the validity of the above integrative approach.
Questioning the Vulnerable Plaque Hypothesis

Considerable issues are currently being raised with regard to the vulnerable plaque hypothesis context, especially its clinical significance.\(^5,7,120\) Despite vulnerable plaque features presence having high sensitivity in cases of acute events, prospective studies, such as Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT),\(^79\) VH-IVUS in Vulnerable Atherosclerosis (VIVA),\(^77\) and the European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis (ATHEROREMO-IVUS),\(^78\) have consistently shown that their positive predictive value is low, implying low prognostic value on an individual basis, used in addition to classical risk-stratification factors. In the same framework, the PREDICTION study only demonstrated an ability for IVUS and shear stress features to predict plaque enlargement and lumen narrowing, not acute events.\(^80\) Failure of a shear-stress inclusive approach to define plaque vulnerability may be related to IVUS resolution, considerably inferior to that of OCT. Moreover, in the recently presented 2-year follow-up of the COLOR registry,\(^93\) NIRS-determined culprit plaque vulnerable phenotype was not associated with a difference in major adverse cardiovascular events occurrence (5.4\% vs 6.3\% in the nonvulnerable plaques; \(P=0.41\)), suggesting that a stented lesion has the same possibility to cause a new clinical event regardless of its type. In fact, adverse events during follow-up were more commonly related to nonculprit lesions; however, outcomes for the NIRS-defined vulnerable nonculprit plaques have not yet been analyzed. In conjunction, the full results from the COLOR and LRP studies (NCT02033694)\(^92\) are expected to definitely answer whether NIRS fares any better in identifying plaques prone to causing future events.

Recent findings appear to suggest that the notion of nonstenotic plaques underlying ACSs is a misconception, given that, when having been assessed close to the episode of which they were the culprit, plaques appear severely stenotic, having undergone a period of accelerated growth.\(^79,121\) Although vulnerable plaques may carry high lipid burdens, masked by their expansive remodeling, 1 of the major tenets of the vulnerable plaque hypothesis is that stenosis degree has little impact on the plaque’s fate, compared to its structural features (although nothing actually precludes it from being severely stenotic).\(^2\) However, this controversy can be reconciled by considering that plaques with accelerated progression are, in fact, vulnerable plaques, fueled by repeated episodes of hemorrhage and subclinical (healed) rupture and erosion.\(^122\)

Studies suggesting plaques may alternate between vulnerable and nonvulnerable phenotypes\(^123\) cast doubt on the significance of diagnosing plaque vulnerability and, conversely, suggest that nonvulnerable plaques may transition into an unstable morphology and suffer rupture or erosion. The stochastic (by current knowledge), rather than deterministic, nature of plaque progression is indirectly supported by the finding that extensive nonobstructive atherosclerosis confers similar risk for MI and sudden death as obstructive, but less-extensive, disease.\(^124\) Additionally, occurrence of clinical events heavily depends on blood and myocardial features (Figure 2); thus, significance of treating rupture prone plaques becomes unclear. However, it is not inconceivable that plaque interdependence may extend well beyond an observed domino-like effect (a destabilized plaque releasing mediators knocking others—even in remote vascular beds—out of balance).\(^125\) More specifically, flow alterations following a silent event or even a successful coronary intervention could inevitably, and currently unpredictably, alter the course of even distant lesions. Finally, the number of nonculprit, asymptomatic, potentially type-switching plaques may be such, especially in cases of high atherosclerotic burden\(^5\) that renders, in combination with the above, all efforts at localized “vulnerability-guided” treatment, without the ability to accurately assess implications futile, if not dangerous.\(^126\)

Despite the above, the apparent shortcomings of the vulnerable plaque hypothesis are not attributed to it having been superseded by our ability to prevent, diagnose, and treat coronary atherosclerosis. Rather, current widespread interpretation and focus on imaging and still-frame structural features have significantly diverged from the original concept, with regard to which we have only covered half the necessary path.\(^46\) More specifically, renewed focus on extrinsic effects on plaques and development of accurate and usable computational models\(^127\) will allow for improved assessment of plaques prone to destabilization of any form. Large, prospective, clinical trials will be mandated to acquire relevant data to be used in the development of appropriate vulnerability criteria. Although this will only apply to plaque destabilization, not hard clinical event prognosis, an accurate model incorporating all additional blood, myocardium, and patient-related parameters (indeed replacing the plaque vulnerability concept) is not expected to be available in the foreseeable future.

Regarding treatment options, it is true that numerous vulnerable plaques usually coexist in patients at risk for cardiovascular events.\(^128\) This, in combination with the domino effect during an ACS, potential for plaque morphology alteration with regression of the vulnerable phenotype and presence of further determinants of clinical outcome (vulnerable blood—vulnerable myocardium) argue against isolating and locally treating vulnerable plaques, and in favor for implementing systemic atherosclerosis treatment approaches,\(^129–131\) interpreting presence of these plaques to signify the degree of its progression in terms of natural history. Exceptions to the above may arise in cases of
Current Perspectives for Plaque Vulnerability

Stefanadis et al

nonculprit destabilized plaque detection during an acute event (potential for domino effect, as suggested by findings of the CvLPRIT [Complete versus Lesion-only Primary PCI trial] trial\(^{132}\)), presence of accelerated plaque progression with increasing stenosis (nonetheless requiring close patient follow-up), and establishment of clinically applicable criteria for imminent plaque destabilization.\(^{114}\) Thus, in this aspect, more judicious use of targeted localized therapies is warranted, as indeed suggested by vulnerable plaque skeptics.

**Current and Future Perspectives**

In addition to the classical armamentarium, several newer conceptual and systemic treatment approaches for reducing atherosclerosis burden and preventing its progression are now being actively pursued.

**Autophagy** is a cellular process affecting both lipid accumulation and inflammation. In its kernel, [autophagy describes the process through which cells are able to digest some of their components (ranging in size from signal molecules and lipids to organelles)],\(^{133}\) and reclaim usable core materials, such as aminoacids.\(^{134}\) The biological role of autophagy, somewhat counterintuitive, appears to lie not only in ensuring recycling of damaged or degraded molecules, especially long-lasting ones, but also in allowing cells to regulate processes, such as inflammation, by degrading triggering stimuli, thus ending their effects.\(^{135,136}\) Master regulators of autophagy include the mammalian target of rapamycin complex and AMP-activated protein kinase.\(^{137}\) Additional autophagy activating stimuli include endoplasmic reticulum stress (caused by misfolded proteins), ROS, and modified lipids, such as oxidized LDL.\(^{138,139}\) Reliance of cellular protein renewal on autophagy and inhibitory effects of...
energy and nutrient abundance on the latter have given rise to
the hypothesis that autophagy status plays a crucial role in
determining vascular age (vessels being under continuous
stress and in need of replacing worn components). Research
findings have confirmed the above and consequently provided
a plausible basis for the well-known adage relating reduced
caloric intake to longevity. On the other hand, overstimulation
of autophagy ultimately leads to cell death and plaque
destabilization attributed to destruction of necessary struc-
tures to ensure survival.140

In the context of atherosclerosis, dysregulation of
autophagy has been described to affect endothelial cells,
SMCs, and macrophages.135 More specifically, endothelial
cells depend critically on autophagy for maintenance of
proper function, and the nitric oxide (NO) system has been
shown to rely on presence of normal autophagy levels
(increases in endothelial NO synthase).141 Contact of
endothelial cells with components of the ECM induces
autophagy, and the latter may inhibit neoangiogenesis.142
Effects of autophagy on smooth muscle include inhibition of
cell death following exposure to lipid peroxides, thus stabil-
izing lesions.138 The most significant effects of autophagy on
atherosclerosis, however, are related to macrophages. In
addition to the established cytoplasmic cholesterol efflux,
formation of autophagosomes encircling lipid droplets allows
for a second pathway contributing to the removal of lipid
material from plaques.143 Interestingly, inflammatory and lipid
mediators (interleukin-6 and oxidized LDL), have been shown
to inhibit macrophage autophagy in a vicious circle.144 Indeed,
autophagy inhibition and stimulation, often in tandem with
apoptosis stimulation and inhibition, have been shown to
promote and arrest, respectively, atherosclerotic plaque
progression.145

microRNAs (miRNAs) are small, noncoding RNA molecules
that act as post-transcriptional regulators of gene expres-
sion.146 In atherosclerotic plaques, alterations in miRNA
signatures have been found in all major involved cell types,
with macrophage and endothelial-cell–derived miRNAs pro-
moting plaque destabilization (through promotion of inflam-
mation and angiogenesis, respectively).147 Conversely, SMC
miRNA profile may be modulated to increase plaque cap
integrity, and thus stability, by either switching them to a less-
synthetic, more-contractile phenotype, improving plaque
mechanical strength, or inducing increased production of
collagen to increase fibrous cap thickness.148 Modulation
involves both upregulation (by administration of miRNA mimics)
and downregulation (through use of antagonirs and
miRNA sponges). Notable, the miRNA approach is the only
one able to address all aspects of plaque destabilization
attributed to miRNA involvement in all phases of atheroscle-
rosis, efficiency of the miRNA gene expression control
mechanism, and the potential to include multiple miRNAs in
a single vector. Finally, yet other miRNAs have been shown to
act by affecting autophagy149 and be upregulated in areas of
increased endothelial shear stress. Despite several more-
promising in vitro and animal studies,150 clinical application
of miRNA manipulation is currently impeded by lack of adequate
vectors and off-target effects.

The notion of cell senescence is also being strongly
implicated in atherosclerosis in current studies. In principle,
senescence is a ubiquitous biological process underlying not
only biological ageing and tissue degeneration, but tissue
remodeling as well (removal of differentiated cells with limited
functional potential and replacement by other from the
progenitor cell pool).151 Thus, the established fact of (biolog-
ical) age being the strongest predictor and risk factor for
vascular disease is put into perspective. Broadly, cell senes-
cence can be classified as replicative (associated with
telomere shortening), stress-induced premature senescence
(not associated with telomeres per se, but exhibiting the same
biochemical changes arresting cell-cycle progression), and
oncogene induced, with only the former 2 involved in
atherosclerosis progression. In addition to changes in telom-
eres, chromatin structure (switch to heterochromatin—trans-
scriptionally quiescent), and inhibition of cell-cycle completion
promoting proteins (mainly cyclin-dependent kinases), senes-
cent cells display a characteristic secretory profile, including
specific cytokines.152,153 Although, in principle, a method to
promote senescent cell clearance by phagocytosis (efferocyt-
osis) and replacement, long-term persistence of this secre-
tory phenotype leads to disproportional proliferation,
angiogenesis, endothelial dysfunction, and inflammatory cell
recruitment.151

In general, the role of senescence in atherosclerosis and
plaque vulnerability appears to be related to both exhaustion
of replicative potential of cells attributed to constant need
for replenishment of disease-related losses and premature
induction of functional handicaps (cell-cycle arrest) not only
precluding self-renewal (autophagy and synthesis of compo-
nents), but also inducing a noxious secretory phenotype.
Senescence has been found to occur in both SMCs and
endothelial cells, rendering them dysfunctional. Verily,
presence of senescent SMCs has been linked to atheroge-
nesis and presence of unstable plaque features, such as
large necrotic core and thinner fibrous cap (potentially
mediated by senescence-related cytokines),154 whereas
senescent endothelial cells are characterized by both NO
synthase uncoupling and over-response to inflammatory
stimuli.155

Significant advances in the understanding of inflammation
have led to the notion that inflammation abatement is an
active, rather than passive, process.156 Specialized proresolv-
ing mediators (SPMs) are a group of structurally related
signaling molecules derived from polyunsaturated fatty acids
acted upon by 1 or a combination of lipoxygenase, cyclooxygenase, and cytochrome P450 monooxygenase enzymes (thus nonselective inhibition of lipoxygenase may not always be beneficial). Main subclasses are resolvins, maresins, protectins, and lipoxins. More broadly, they are considered autacoids (στυτοκύκτος, “self-heal”), hormones produced, acting, and catabolized locally. It appears that they constitute the second part of a negative feedback loop, being produced by inflammatory cells and acting on them and other cells in the tissue vicinity to promote healing, including efferocytosis stimulation, and quench proinflammatory stimuli. Moreover, SPMs initiate a positive feedback loop for the firm induction and progression of the reparatory process. In atherosclerotic plaques, in accord with the concept of chronic inflammatory activation, plaque progression and assumption of a vulnerable phenotype are both related to increased levels of proinflammatory lipid mediators (such as leukotriene B4) and decreased levels of SPMs, evidencing that, in chronicity, inflammation has gone awry. Thus, inflammation control should involve not only suppression of promoting pathways, as is the current treatment paradigm in atherosclerosis, by means of medications (eg, statins), but also reinforcement of those promoting healing and dampening of inflammatory responses. Recent research has established that exogenous administration of a cocktail of SPMs does indeed lead to plaque stabilization by halting further engagement of the necrotic core, leading to increases in the numbers of SMCs and cap thickness and altering macrophage phenotype to a reparatory one (M2).

Further pathways of interest for research and putative significance for the natural history of atherosclerosis have been identified. Pyroptosis is among them and refers to a form of proinflammatory cell death of immune cells, following detection of foreign antigens within, whereupon cells commit suicide while releasing immune-stimulatory molecules. Differences from apoptosis include dependence on caspase 1 activation and formation of the inflammasome (as opposed to caspases 8 and 9 and apoptosome, respectively). The difference from necroptosis lies in the occurrence in immune (as opposed to tissue) cells. Studies have shown that intracellular oxidized LDL may act as an inductor of macrophage pyroptosis, through a mitochondrial-DNA–dependent pathway. Although apoptosis, necroptosis, and autophagy have been reported in atherosclerosis, it is entirely possible that pyroptosis of immune cells is also involved (and thus apoptotic foam cells are, at least in part, actually pyroptotic cells), more dynamically contributing to plaque destabilization. On more-conventional grounds, generalized immunosuppressive treatment has been implemented with favorable results whereas therapies targeted to specific components (eg, inhibition of MMPs) have yielded encouraging results.

### Table 3. Vulnerable Plaque Conundrum

<table>
<thead>
<tr>
<th>What it originally meant</th>
<th>What it should mean</th>
<th>How it is currently interpreted in the majority of literature</th>
</tr>
</thead>
<tbody>
<tr>
<td>A plaque that is the culprit lesion for an acute coronary event</td>
<td>A plaque that is prone to rupture when all intrinsic and extrinsic effects are taken into account (regardless of structure)</td>
<td>A plaque with specific morphological features—usually referring exclusively to thin cap fibroatheromas</td>
</tr>
</tbody>
</table>

This table attempts to summarize the different connotations inherent in the term “vulnerable plaque.” It can be appreciated that a teleological approach has shifted toward a utilitarian one, allowing for easier classification of plaques as “vulnerable” or not, yet depriving this characterization of prognostic implications.

### Conclusions

The concept of vulnerable plaque was developed with the intent of formally defining and describing atherosclerotic plaques having caused acute clinical events (a posteriori). Need for clinical applicability led to definition shifting toward plaques prone to causing events and by extension prone to destabilization (rupture, erosion). Most subsequent clinical studies further narrowed the scope by focusing on intrinsic (structural) determinants of instability, such as quantitative and qualitative composition and remodeling. Attributed to the neglect accorded to effects of extrinsic stressors (eg, dynamic pressure/pressure head, turbulent/laminar flow; see Figure 1), and the routine use of a single imaging modality in plaque assessment, this led to plaques considered nonvulnerable, under the current concept, to be found causing events.

Despite the above, the vulnerable plaque concept has led to tremendous advances in our understanding of pathogenesis and treatment of atherosclerosis, along with substantial improvement of the relevant technological armamentarium. Results from newer studies and trials appear to suggest that a change of approach to the vulnerable plaque concept is mandated to further improve patient diagnosis and treatment. However, a return to the fundamentals of the vulnerable plaque hypothesis appears more appropriate (Table 3).

In particular, improvement in the assessment of the complex interplay between intrinsic and extrinsic factors mentioned above (Figure 1) by use of advanced computational models is crucial in more accurately determining which plaques are truly vulnerable and thus allow for a more-accurate estimate of their “natural future” (Figure 2). Their detection should be interpreted as a marker of advanced atherosclerosis progression, in the context of such systemic alterations as deranged autophagy, SPM and noncoding RNA regulation, and treated both aggressively and systematically.
The fundamental question whether and under what circumstances localized treatment of plaques should be pursued is further complicated by two factors: The ability of plaques to alternate between different structural phenotypes (thus changing their location in the Figure 1 curve) and plaque interdependence, as described above. It could be safely said, based on large trials’ evidence, that treating current (nonculprit) vulnerable plaques does not affect disease progression and patient course. However, whether this will hold true in the future, with integrative approaches, incorporating advanced computational models, and changing the working definition of vulnerability, cannot be at present determined, pending development of such tools and related prospective trials.

The vulnerable blood and vulnerable myocardium concepts should be brought back into focus to allow for assessment of the vulnerable patient by determining which plaque-blood-myocardium combinations are prone to leading to catastrophic events (that may actually be arrhythmic rather than ischemic). On the other hand, not all silent events are innocent: It is conceivable that they might alter, by mechanisms discussed previously, the course of other plaques, in the long term—although at present this is merely conjectural and hypothesis generating.

In conclusion, although the vulnerable plaque is a valid concept in principle, holding great promise for future research, current interpretation of (incomplete) data for vulnerability assessment has rendered it inaccurate. Resources could be more effectively redirected toward large-scale efforts to reduce the epidemiological atherosclerosis burden, for which there is solid evidence for improving life expectancy and quality, and also toward developing more sophisticated models for an integrative approach to plaque assessment. In any case, it should be kept in mind that “preventing is better than treating.” Thus, guided localized treatment of plaques, rather than systemic approach to patients, is, in the great majority of cases and given lack of reliable simulation models, not advisable at present for reasons of effectiveness and safety.

Disclosures
None.

References
Current Perspectives for Plaque Vulnerability  Stefanidis et al

31. Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev
33. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM,
36. Tanaka A, Imanishi T, Kitabata H, Kubo T, Takarada S, Tanimoto T, Kuroi A,
38. Kramer MC, Rittersma SZ, de Winter RJ, Ladich ER, Fowler DR, Liang YH,
40. Tuenter A, Selwanes M, Arias Lorza A, Schubriers JC, Speelman L, Cibis M,
41. van der Lugt A, de Bruijn M, van der Steen AF, Vernooy MW,
42. Weissleder R. Multimodality molecular imaging identi
43. Ferrante G, Nakano M, Prati F, Niccoli G, Mallus MT, Ramazzotti V, Montone
44. Toutouzas K, Benetos G, Karanasos A, Chatzizisis YS, Giannopoulos AA,
45. Liang X, Xenos M, Alemu Y, Rambhia SH, Lavi I, Kornowski R, Gruberg L,
46. Toutouzas K, Schubriers JC, Gonzalez Lopez N, Gijsen FJ, van der Giessen AG,
47. Liang X, Xenos M, Alemu Y, Rambhia SH, Lavi I, Kornowski R, Hoole SP, West
48. Tuenter A, Selwanes M, Arias Lorza A, Schubriers JC, Speelman L, Cibis M,
49. Wentzel JJ, Schubriers JC, Gonzalez Lopez N, Gijsen FJ, van der Giessen AG,
50. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from
51. Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev
53. Cardoso L, Weinbaum S. A mechanistic analysis of the role of microcalci-
54. Teng Z, Brown AJ, Calvert PA, Parker RA, Obaid DR, Huang Y, Hoole SP, West
55. Finet G, Ohayon J, Rioufol G. Biomechanical interaction between cap
56. Ambrose JA, Tannenbaum MA, Akeel P, Davies MJ. A macro and micro view of coronary vascular insult in ischemic
57. Ferrante G, Nakano M, Prati F, Niccoli G, Mallus MT, Ramazzotti V, Montone
60. Arbusini E, Grassi M, Diefio M, Pucci A, Brambro S, Ardissoni D, Angoli L,
63. Ferrante G, Nakano M, Prati F, Niccoli G, Mallus MT, Ramazzotti V, Montone
64. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlmann Y, Weiss DS,
65. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlmann Y, Weiss DS,
66. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlmann Y, Weiss DS,
67. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlmann Y, Weiss DS,
68. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlmann Y, Weiss DS,
69. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlmann Y, Weiss DS,
Current Perspectives for Plaque Vulnerability


**Key Words:** atherogenesis • treatment • vulnerable plaque
Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives
Christodoulos Stefanadis, Christos-Konstantinos Antoniou, Dimitrios Tsiachris and Panagiota Pietri

*J Am Heart Assoc.* 2017;6:e005543; originally published March 17, 2017;
doi: 10.1161/JAHA.117.005543

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/6/3/e005543